Argenx US Patent-Cliff Exposure & CMS Drug Spending Portfolio

Argenx US (US): 1 reconciled FDA prescription therapies, $142.1M 2024 CMS Part D & Medicaid spend, and $66,928 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$142.1M
2024 Medicare Part D Spend$126.1M
2024 Medicaid Spend$16.0M
California HCAI SB 17 FilingsSpecialty launch notice ($66,928 intro WAC)